RhumbLine Advisers’s Mineralys Therapeutics MLYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $725K | Buy |
53,596
+14,235
| +36% | +$193K | ﹤0.01% | 2424 |
|
|
2025
Q1 | $625K | Sell |
39,361
-1,195
| -3% | -$19K | ﹤0.01% | 2424 |
|
|
2024
Q4 | $499K | Buy |
40,556
+695
| +2% | +$8.56K | ﹤0.01% | 2679 |
|
|
2024
Q3 | $483K | Sell |
39,861
-1,218
| -3% | -$14.8K | ﹤0.01% | 2720 |
|
|
2024
Q2 | $481K | Buy |
41,079
+18,519
| +82% | +$217K | ﹤0.01% | 2708 |
|
|
2024
Q1 | $291K | Buy |
22,560
+2,091
| +10% | +$27K | ﹤0.01% | 2994 |
|
|
2023
Q4 | $176K | Buy |
20,469
+3,295
| +19% | +$28.3K | ﹤0.01% | 3245 |
|
|
2023
Q3 | $163K | Buy |
17,174
+2,279
| +15% | +$21.7K | ﹤0.01% | 3262 |
|
|
2023
Q2 | $254K | Buy |
14,895
+3,935
| +36% | +$67.1K | ﹤0.01% | 3108 |
|
|
2023
Q1 | $172K | Buy |
+10,960
| New | +$172K | ﹤0.01% | 2769 |
|